Abstract

The central molecular event underlying prion diseases involves conformational change of the cellular form of the prion protein (PrPC), which is a sialoglycoprotein, into the disease-associated, transmissible form denoted PrPSc. Recent studies revealed a correlation between the sialylation status of PrPSc and incubation time to disease and introduced a new hypothesis that progression of prion diseases could be controlled or reversed by altering the sialylation level of PrPC. Of the four known mammalian sialidases, the enzymes that cleave off sialic acid residues, only NEU1, NEU3 and NEU4 are expressed in the brain. To test whether cellular sialidases control the steady-state sialylation level of PrPC and to identify the putative sialidase responsible for desialylating PrPC, we analyzed brain-derived PrPC from knockout mice deficient in Neu1, Neu3, Neu4, or from Neu3/Neu4 double knockouts. Surprisingly, no differences in the sialylation of PrPC or its proteolytic product C1 were noticed in any of the knockout mice tested as compared to the age-matched controls. However, significantly higher amounts of the C1 fragment relative to full-length PrPC were detected in the brains of Neu1 knockout mice as compared to WT mice or to the other knockout mice. Additional experiments revealed that in neuroblastoma cell line the sialylation pattern of C1 could be changed by an inhibitor of sialylatransferases. In summary, this study suggests that targeting cellular sialidases is apparently not the correct strategy for altering the sialylation levels of PrPC, whereas modulating the activity of sialylatransferases might offer a more promising approach. Our findings also suggest that catabolism of PrPC involves its α-cleavage followed by desialylation of the resulting C1 fragments by NEU1 and consequent fast degradation of the desialylated products.

Highlights

  • Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative disorders that can be sporadic, inheritable or transmissible in origin [1]

  • Like full-length PrPC, C1 and C2 fragments are attached to the plasma membrane via a glycosylinositol phospholipid anchor (GPI) anchor and conserve two N-linked glycans [28, 29, 36]

  • Our earlier studies revealed a correlation between sialylation status of PrPC and the propensity of PrPC to engage in replication of PrPSc in vitro

Read more

Summary

Introduction

Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative disorders that can be sporadic, inheritable or transmissible in origin [1]. PrPC undergoes posttranslational modifications that involve attachment of up to two N-linked glycans to residues Asn-180 and Asn-196 and a glycosylinositol phospholipid anchor (GPI) to the C-terminal residue Ser-230 (residue numbers are given for mouse PrPC) [3,4,5]. Each of the two N-linked glycans can carry up to five terminal sialic acid residues that are linked to the galactose residues at the C-6 or C-3 positions [6, 7]. In addition to sialylation of N-linked glycans, a single sialic acid was found on the GPI anchor of PrPC [3]. Considering heterogeneity in sialylation level of individual glycans and GPI, each PrPC molecule could contain from 0 to 11 sialic acid residues

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call